Phase 2TerminatedAge-related condition

X-82 to Treat Age-related Macular Degeneration

A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD

Sponsor
Tyrogenex (Industry)
Enrollment
157 enrolled
Conditions
Age-Related Macular Degeneration (AMD); Macular Degeneration; Exudative Age-related Macular Degeneration; AMD; Macular Degeneration, Age-related, 10; Eye Diseases; Retinal Degeneration; Retinal Diseases
Interventions
X-82; Anti-VEGF; Placebo
Ages
adults, older adults
Registry
NCT02348359

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.

Primary outcomes

  • Mean Change in Visual Acuity Score From Day -1 to Week52

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered